Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Blueshift Asset Management LLC

Blueshift Asset Management LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 284.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,303 shares of the biopharmaceutical company's stock after purchasing an additional 964 shares during the period. Blueshift Asset Management LLC's holdings in Regeneron Pharmaceuticals were worth $928,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Truvestments Capital LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth $39,000. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the period. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $28,000. Finally, Larson Financial Group LLC grew its position in shares of Regeneron Pharmaceuticals by 127.3% in the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 28 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.4 %

Shares of REGN stock traded up $2.52 during trading hours on Monday, hitting $661.00. The company had a trading volume of 962,350 shares, compared to its average volume of 635,787. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company's fifty day moving average is $688.31 and its 200 day moving average is $809.71. The stock has a market capitalization of $72.26 billion, a PE ratio of 17.27, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $11.86 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on REGN. Bernstein Bank decreased their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Finally, Piper Sandler reduced their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.